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Endothelial cell apoptosis contributes to the vascular remodeling in Pulmonary 
Hypertension. But the pathways causing endothelial cell apoptosis are only partially 
understood. Current concepts indicate a role for chronic inflammation in Pulmonary 
Hypertension, yet innate RNA recognition may also be a protective mechanism in the 
vasculature.   
 
$%
Here we demonstrate, for the first time, that Toll9like receptor 3 (TLR3) expression is 
reduced in lung tissue and endothelial cells from patients with Pulmonary Hypertension 
and show and that TLR3 deficiency increases susceptibility to apoptosis 
and Pulmonary Hypertension. We further show that the TLR3 agonist and double 
stranded RNA Polyinosinic:polycytidylic acid increases TLR3 expression and reduces 
established Pulmonary Hypertension. Our data suggest that this protective upregulation 
of TLR3 involves induction of interleukin 10. We propose that TLR3 expression is 
required for endothelial cell homeostasis and that restoring TLR3 signaling may be a 
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novel avenue to complement existing treatment strategies in Pulmonary Hypertension. 
#

Pulmonary Hypertension, Inflammation, Endothelium, Vascular Biology, 
Gene expression 
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'Pulmonary arterial hypertension (PAH) is characterized by vascular cell 
proliferation and endothelial cell apoptosis. Toll9like receptor 3 (TLR3) is a receptor for 
double9stranded RNA and has been recently implicated in vascular protection.  
(#
)The goal was to study the expression and role of TLR3 in PAH and to 
determine whether a TLR3 agonist reduces Pulmonary Hypertension in preclinical 
models.  
*Lung tissue and endothelial cells from PAH patients were investigated by 
polymerase chain reaction, immunofluorescence and apoptosis assays. TLR39/9 and 
TLR3+/+ mice were exposed to chronic hypoxia and SU5416. Chronic hypoxia or chronic 
hypoxia/SU5416 rats were treated with the TLR3 agonist polyinosinic:polycytidylic acid 
[Poly(I:C)].  
*	*'TLR3 expression was reduced in PAH patient lung 
tissue and endothelial cells, and TLR39/9 mice exhibited more severe Pulmonary 
Hypertension following exposure to chronic hypoxia/SU5416. TLR3 knockdown 
promoted double9stranded RNA signaling other intracellular RNA receptors in 
endothelial cells and this was associated with greater susceptibility to apoptosis, a known 
driver of pulmonary vascular remodeling. Poly(I:C) increased TLR3 expression via 
interleukin910 in rat endothelial cells. 	, high dose Poly(I:C) reduced Pulmonary 
Hypertension in both rat models in proof9of9principle experiments. In addition, Poly(I:C) 
also reduced right ventricular failure in established Pulmonary Hypertension. 

Our work identifies a novel role for TLR3 in PAH based on the findings that 
reduced expression of TLR3 contributes to endothelial apoptosis and pulmonary vascular 
remodeling.  
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" 	Pulmonary Hypertension, toll9like receptor 3, endothelial cell, double 
stranded RNA, apoptosis 
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 Pulmonary arterial hypertension (PAH) is a severe and progressive disease of the 
pulmonary arterial bed and is characterized by occlusive remodeling of pulmonary 
arteries (1). While current therapies improve quality of life and prognosis, PAH remains a 
life9limiting condition (2). One reason is that the current treatment options do little to 
change the chronic pathology in the pulmonary arteries (3). Apoptosis of endothelial cells 
(EC) contributes to lung vascular remodeling by promoting selection of 
apoptosis9resistant EC, initiating proliferation of vascular smooth muscle cells (VSMC), 
and directly, vascular pruning (4−11). Multiple pathogenic mechanisms likely 
contribute to EC apoptosis (7–10) and identifying targetable mechanisms remains an 
important goal (11).  
Recently, a protective role in blood vessels was shown for Toll9like receptor 3 
(TLR3), a member of the TLR family of innate immune receptors (12). TLR3 responds to 
viral and synthetic double9stranded (ds) RNA, as well as RNA released from healthy and 
apoptotic cells (13; 14). TLR3 not only regulates RNA signaling by its primary localization 
at the endosomal membrane, but TLR3 can also influence RNA signaling through 
additional cytosolic RNA receptors. These RNA receptors include Retinoic Acid9inducible 
Gene9I (RIG9I) and Melanoma Differentiation9Associated Protein95 (MDA95) (15; 16).  
In addition to the role of TLR3 in the intracellular response to RNA, a protective 
effect has been shown for the synthetic dsRNA and TLR3 agonist 
polyinosinic:polycytidylic acid [Poly(I:C)]. This protection was in part mediated via the 
anti9inflammatory cytokine interleukin910 (IL910) (12; 17) 
Based on this evidence, we hypothesized that TLR3 signaling protects lung 
vasculature, and that promoting TLR3 signaling would reduce PH. We therefore 
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examined TLR3 expression and show that endothelial expression of TLR3 is reduced in 
occlusive vascular lesions, pulmonary artery EC (PAEC) and lung tissue from patients 
with PAH. TLR3 knockout exaggerated PH and endothelial apoptosis in mice exposed to 
chronic hypoxia and SU5416 (cHx/Su). 	, exposure to high, but not low, 
concentrations of dsRNA promoted TLR3 expression by increasing IL910 expression in 
CD117+ lung EC. 	, treatment with high dose Poly(I:C) prevented and reduced 
experimental PH in rats in proof9of9principle experiments, ameliorating vascular 
remodeling, apoptosis and proliferation in pulmonary arteries. Some of the results of 
these studies have been previously reported in the form of abstracts (18–20). 
 
*.(


De9identified human lung tissue was obtained from the Department of Pathology, 
University of Colorado Denver and the tissue repository of the Pulmonary Hypertension 
Breakthrough Initiative (PHBI). PAEC were isolated by the University of Pittsburgh Cell 
Processing Core and the PHBI in a de9identified manner under PHBI9approved protocols 
and in compliance with the Institutional Review Boards. Control samples and cells were 
from failed donor lungs and lung tissue resections for other diseases, e.g., cancer. The 
Institutional Review Boards have approved the tissue collection at the respective 
institutions. Due to the use of de9identified tissues and cells, the study was deemed 
non9human subjects research by the Office of Research Subjects Protection at Virginia 
Commonwealth University. 
 
	 
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All animal experiments were approved by the Institutional Animal Care and 
Utilization Committees in accordance with the Health Research Extension Act (Public 
Law 999158) at Virginia Commonwealth University and the U.K Home Office Animals 
(Scientific Procedures) Act of 1986 at the University of Sheffield. The procedures followed 
the "Guide for the Care and Use of Laboratory Animals", National Academy Press, 
Washington, D.C. 1996. Additional details regarding the experimental models and strains 
are found in an online data supplement. The treatment was applied as follows: Preventive 
strategy (cHx and cHx/Su): 1 mg/kg (only cHx/Su), 10 mg/kg Poly(I:C) or vehicle (PBS) 
three times a week by intraperitoneal (i.p.) injection from day 1921; Therapeutic strategy 
(cHx/Su): 10 mg/kg Poly(I:C) three times a week i.p. from day 29942. Additional controls 
were naive rats treated with 10 mg/kg Poly(I:C) or vehicle for 14 days. Animals were 
randomly assigned to the treatment groups. At day 21 or 42, the animals underwent 
echocardiographic and hemodynamic evaluation under anesthesia with Ketamine 100 
mg/kg and Xylazine 15 mg/kg i.p., followed by tissue harvest after exsanguination (10; 
21). In mice, right ventricular pressure9volume measurements were collected under 
isoflurane anesthesia as previously described (22).  
 
Additional detail on the methods for cell culture experiments and animal experimentation 
is provided in an online data supplement. 
 



Data were compared using Student’s t9test (2 groups), or one or two9way ANOVA 
(more than 2 groups), following by multiple comparison testing using the Holm9Sidak or 
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Sidak tests. The calculations were performed using Prism 6.0 (GraphPad Software Inc., 
San Diego, CA). A 
value of <0.05 was considered significant. 
 
'.-/
'
/'
 /'	)	
.
 Triple immunofluorescence (IF) showed reduced endothelial TLR3 staining in 
remodeled pulmonary arteries from PAH patients. In arteries with intima lesions, a part of 
the endothelium has lost TLR3 expression (Figure 1). Loss of TLR3 was widespread in 
the endothelium of concentric and plexiform lesions. In contrast, pulmonary artery 
endothelium of control subjects had strong TLR3 expression (Figure 1). We further 
confirmed reduced endothelial TLR3 expression in cultured PAEC and PAH lung tissue 
(Figure 2A9D). We further studied the timing of TLR3 expression in the cHx and cHx/Su 
PH models. TLR3 protein expression was lower in cHx/Su lung tissue at day 21 (Figure 
2E9F), and cHx and cHx/Su animals had reduced fraction of TLR3+ EC (Figure 2G9H).  
Then, we evaluated TLR3 deficiency . Naive TLR39/9 mice failed to develop 
spontaneous PH (Figure 2I9L). However, media wall thickness (MWT), fraction of 
muscularized arteries and PH were aggravated in TLR39/9 mice following exposure to 
cHx/Su (Figure 2I9L). These data suggest that loss of TLR3 altered vascular function, 
leading to increased remodeling. Because of the importance of endothelial apoptosis in 
PAH pathobiology, we next sought to determine the link between TLR3 deficiency, 
endothelial apoptosis and PH. 
 
/'

	
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 Then we studied a potential driver of PH, apoptosis, in relation to TLR3 expression. 
While we found no apoptosis in TLR39expressing endothelium from control subjects, we 
found TLR39deficient apoptotic intima cells in PAH lesions (online supplement Figure 
E1A). Further analysis revealed an increased fraction of cleaved caspase93+ intima cells 
in PAH pulmonary arteries (online supplement Figure E1B9C). Likewise, pulmonary 
arteries of TLR39/9 mice had more apoptotic EC after 21 days of cHx/Su (online 
supplement Figure E1D9E). We did not find increased apoptosis at early timepoints (1 or 6 
days) in cHx/Su rats (online supplement Figure E2).  
 
/'

	
 	, PAH PAEC had elevated frequency of background apoptosis (Figure 
3A9B) and we tested whether TLR3 deficiency promotes endothelial apoptosis using two 
approaches. First, we silenced TLR3 expression in rat lung CD117+ EC using single 
hairpin RNA (shRNA). These cells were isolated from the lungs of naive rats, expressed 
the endothelial marker vWF, formed angiogenic tubes and were clonally expandable 
(online supplement Figure E3). TLR3 knockdown increased the frequency of background 
apoptosis (Figure 3C9E). As second approach, we induced loss of TLR3 in human PAEC 
using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 
technology. We found in TLR3 CRISPR cells a substantial reduction in TLR3 protein 
(Figure 3F9H), which was maintained after passage (online supplement Figure E4). 
Because PAEC were in passage 5 or higher at the start of the experiment, we did not 
perform a selection of TLR39 PAECs, retaining a small fraction of TLR3+ cells. TLR3 
CRISPR PAEC had higher baseline expression of (RIG9I) and 		(MDA95) 
(Figure 3I), and a higher baseline apoptosis rate with an exaggerated apoptotic response 
Page 10 of 775
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 
11 
to serum starvation (Figure 3J9K). TLR3 CRISPR also impaired migration . This 
was partially reversed by caspase inhibition, despite a small reduction in gap closure by 
the caspase inhibitor in scrm PAEC (Figure 3L9M). 
 
'
/'0		',)	',	
	
'+!+*1
We then evaluated the subcellular localization of dsRNA by exposing CD117+ EC 
to rhodamine9labeled Poly(I:C) after treatment with scrambled shRNA (shscrm) or 
TLR39targeted shRNA (shTLR3). In shTLR3 cells, Poly(I:C) localized to RIG9I and MDA95 
in the cytoplasm, whereas Poly(I:C) also localized to TLR3 in shscrm cells (Figure 4A). In 
shscrm EC, Poly(I:C) induced expression of and interleukin96 (	), but not 
interleukin910 (	), and decreased expression of endothelin91 () (Figure 4B9E). 
Poly(I:C) failed to induce 	in shTLR3 cells, and upregulation of was substantially 
lower in shTLR3 cells. Knockdown of TLR3 alone elevated expression of 	, 
but not of and 	, indicating that TLR3 deficiency promotes a gene expression 
profile associated with inflammation and vascular remodeling.However, Poly(I:C) 
stimulation increased 	expression substantially in shTLR3 EC.
Our supplemental data show that transfection of Poly(I:C) increased expression of 
	and far more than extracellular addition (online supplement Figure E5). 
This is relevant to our findings, because extracellular addition of Poly(I:C) targets TLR3 
via endosomal uptake, whereas liposomal transfection facilitates interaction between 
Poly(I:C) and both, cytoplasmic and endosomal receptors, increasing synergistic 
signaling (23). 
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2+3			/'0	+/45	6
We then postulated that the release of RNA from damaged cells was insufficient to 
upregulate TLR3. We found that only high concentration of Poly(I:C) increased 
expression of 	and  (Figure 4F9G). Blocking IL910 with a neutralizing antibody 
abolished TLR3 upregulation after Poly(I:C) treatment (Figure 4H). Consistent with 
effective IL910 inhibition, we observed de9repression of CXCL10 (24) (Figure 4I). 
Poly(I:C) increased activation of nuclear factor9κB (NF9κB) p65 and activator protein 1 
(AP91) c9Jun (Figure 4J), and blocking AP91 with SR11302 partially blocked 
Poly(I:C)9induced upregulation of IL910 (Figure 4K). 
 
	2+3
	

 To identify whether different vascular compartments react differently to Poly(I:C) 
stimulation, we compared the gene expression of human lung microvascular EC 
(HLMVEC) and human umbilical vein EC (HUVEC). In both cell lines, we found 
concentration9dependent upregulation of , (RIG9I) and 		(MDA95) 
(online supplement Figure E6A9B)In HUVEC, Poly(I:C) failed to induce 	and 
	, but caused a more substantial induction of and 		. 
 Comparing caspase 3/7 activity of HLMVEC and PAEC, we found that 
Poly(I:C) caused a concentration9dependent increase in apoptosis only in serum9starved 
HLMVEC, but not PAEC (online supplement Figure E7A). Because Poly(I:C) increases 
production of reactive oxygen species (ROS) in systemic endothelium (25), we compared 
ROS production. We found no difference in Poly(I:C)9induced ROS production between 
HUVEC and PAEC (online supplement Figure E7B). 
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
				7'8	
As the loss of TLR3 signaling predisposed to more severe PH we sought to determine in 
proof9of9principle experiments whether activation of this pathway would prevent the 
development of PH. First, we tested Poly(I:C) in naive animals. We detected no increase 
in RVSP and arterial occlusion after treatment with Poly(I:C) (Supplemental Figure E8 
A9C). However, we found an increase in MWT and fraction of apoptotic cells in the artery 
wall after Poly(I:C) treatment (online supplement Figure E8 A, D9F). Then, rats with PH 
induced by chronic hypoxia were treated with Poly(I:C). In our prophylactic treatment 
groups, RVSP was significantly lower in rats treated with Poly(I:C). Reduced PH was 
associated with lower MWT and smaller fraction of fully muscularized arteries (online 
supplement Figure E9A9F). Poly(I:C) treatment did not significantly compromise 
echocardiographic right ventricular cardiac output (online supplement Figure E9D) and it 
ameliorated apoptosis and proliferation in the artery walls (online supplement Figure E9 
G9J). Finally, to further explore whether Poly(I:C) reduces severe PH with vascular 
obliteration, rats with cHx/Su9induced severe PH were treated with Poly(I:C) in 
prophylactic and interventional strategies. We also tested whether Poly(I:C) treatment 
had concentration9dependent effects. Prophylactic high dose Poly(I:C) treatment reduced 
severe cHx/Su PH and vascular occlusion, but had no significant effect on MWT, RV 
cardiac output or the inflammatory cell profile in the lungs of cHx/Su rats (Figure 5A9F and 
online supplement Figure E10). We found that only high dose Poly(I:C) had a protective 
effect (Figure 5A9F). By contrast, low dose Poly(I:C) treatment failed to reduce RVSP and 
vascular obliteration, but increased MWT. Only high dose Poly(I:C) treatment significantly 
reduced the fraction of cleaved caspase93+ (apoptotic) and proliferating cell nuclear 
antigen (PCNA)+ (proliferating) cells in the pulmonary arteries (Figure 5G9J). In addition, 
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high dose Poly(I:C) treatment increased IL910 expression in the lungs of cHx/Su rats 
(Figure 5K9L). Established severe PH and occlusion was ameliorated by high dose 
Poly(I:C) (intervention strategy), although muscularization of pulmonary arteries was not 
significantly reduced (Figure 6A9E). RV cardiac output was improved by Poly(I:C) 
treatment in established PH (Figure 6F) and similar to the prophylactic strategy, numbers 
of cleaved caspase93+ and PCNA+ pulmonary vascular cells were reduced (Figure 6G9J). 
To identify the effect of Poly(I:C) treatment on systemic blood vessels, we investigated left 
ventricular capillary density and apoptotic index. We further found no significant change 
in the capillary density and apoptotic index in the left ventricle of cHx rats after preventive 
treatment with high dose Poly(I:C) (online supplement Figure E11). In contrast, we 
detected increased capillary density and reduced apoptotic index in the left ventricles of 
cHx/Su rats after therapeutic treatment with high dose Poly(I:C) (online supplement 
Figure E12). 
 
+-+(,
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by 
progressive narrowing and reorganization of the pulmonary arteries (1; 26). Although 
increased cell proliferation has been identified in pulmonary vascular lesions, a 
paradoxical increase in endothelial apoptosis is important for the initiation and 
progression of the disease (4; 27–30).  
In this study, we identify the innate immune receptor TLR3 as a novel regulator of 
endothelial apoptosis in PAH. Our data show that loss of TLR3 leads to EC apoptosis and 
that a TLR3 agonist can reduce severe PH in preclinical animal models. There is a 
well9supported paradigm that pro9inflammatory signaling drives pulmonary vascular 
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remodeling in PAH. Our data may therefore appear counterintuitive, however there are 
precedents for protective effects of TLR3 expression and signaling in the systemic 
circulation and our data imply that this pathway also confers protection in the pulmonary 
vasculature (1; 12; 31). 
We found reduced expression of TLR3 in the lungs and PAEC from PAH patients 
and we demonstrated an association between loss of TLR3 and caspase9dependent 
endothelial apoptosis. Extending our studies, we found that TLR39/9 mice have 
more severe PH and vascular remodeling in response to the cHx/Su protocol, likely 
caused by increased endothelial apoptosis. Endothelial apoptosis has been implicated in 
pulmonary vascular remodeling (5; 30; 32) with studies suggesting that early apoptosis 
contributes to increased vascular cell proliferation in PAH (9; 30; 33–35). Some authors 
even suggest endothelial apoptosis as a direct cause of PH due to vascular pruning (4; 
36). Hence, understanding the mechanism of endothelial apoptosis in PH is important to 
derive meaningful treatment strategies. 
TLR3 is a receptor for a broad spectrum of RNAs, including mRNA released from 
dying cells and small interfering RNA sequences without regard of the nucleic acid 
sequence (14–16; 37; 38). Hence RNA is a “damage9associated molecular pattern” for 
TLR3 during the cellular injury response. TLR3 is mainly localized in the endosomal 
membrane, but additional receptors for dsRNA and RNA are found in the cytosol, and 
these include MDA95 and RIG9I (23; 39; 40). In TLR39deficient EC, we found that RNA 
signaling is directed towards these additional RNA receptors, which can induce 
apoptosis, possibly explaining the higher degree of apoptosis in TLR39deficient EC. 
Furthermore, TLR3 knockdown increased expression of endothelin91 and IL96, which are 
implicated in endothelial dysfunction and vascular remodeling (41). Hence, our data 
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indicate that endothelial RNA signaling is dysregulated as a consequence of reduced 
TLR3 expression. Interestingly, although we show that changes in TLR3 expression 
impact upon RNA signaling, it is also possible that loss of function polymorphisms of 
TLR3 could play a role in defective RNA sensing in PAH, similar to a more aggressive 
clinical phenotype observed in patients with TLR3 polymorphisms in idiopathic pulmonary 
fibrosis (42). 
We then tested whether we can treat PH with dsRNA. Our approach, including 
dose and regimen of the dsRNA Poly(I:C), was informed by the findings of Cole  , who 
showed that Poly(I:C) promoted TLR3 expression and protected from arteriosclerotic 
vascular injury (12). Our experiments showed that Poly(I:C) treatment prevented and 
reduced PH, and improved right ventricular failure. Poly(I:C) treatment ameliorated 
apoptosis, proliferation and remodeling in the pulmonary artery wall in two PH models. 
Interestingly, Poly(I:C) did not promote pulmonary inflammation in cHx/Su rats. These 
beneficial effects of TLR3 activation are in contrast to findings by Zimmer  . who 
showed that Poly(I:C) impaired endothelial function and systemic arterial 
re9endothelialization after a denuding injury (25). While the study by Zimmer  
investigated Poly(I:C) in an acute model of large scale vascular denudation, we showed 
protective effects in chronic models of lung vascular remodeling without denuding injury, 
which could already explain the contrasting results. Further differences are Poly(I:C) 
dosage and administration route, and it is possible that tissue9specific differences in RNA 
sensor signaling contribute to the divergent findings. For example, we found that healthy 
extra9pulmonary EC failed to upregulate IL910 and CXCL10 in response to Poly(I:C), but 
had a higher induction of RIG9I and MDA95 than pulmonary EC. When we observed 
detrimental effects of Poly(I:C), this was only in the context of an uninjured pulmonary 
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vasculature. This concept is further supported by the results of a study by Huang and 
colleagues who found that Poly(I:C) induces barrier dysfunction and cytokine 
production in healthy lung endothelium (43). The results by George  also back our 
notion by showing Poly(I:C)9induced upregulation of endothelin91 in healthy lung VSMC 
(44). Taken together, these data imply that endothelial TLR3 expression has a 
homeostatic role in the context of chronic lung vascular remodeling. Our data further 
indicate that Poly(I:C) caused no adverse effect on left ventricular capillary density and 
apoptotic index  in both PH models and therapeutic Poly(I:C) treatment was even 
protective for the left ventricle of cHx/Su rats. Agents to manipulate TLR3 signaling, such 
as the dsRNA rintatalimod, are available and may exert therapeutic effects on vascular 
cells in the context of TLR3 deficiency, as we have observed in PH (45).  
Our data demonstrated that induction of IL910 and TLR3 by Poly(I:C) 
occurred only after high dose treatment. These data imply that high concentrations are 
therefore required to restore TLR3 levels and reduce apoptosis. This offers a potential 
explanation of why constitutive RNA signaling fails to offer protection from vascular 
remodeling; the concentration of RNA internalized following cell injury may simply be too 
low. Although induction of TLR3 and IL910 expression by dsRNA has been demonstrated 
before, induction of TLR3 via IL910 represents a novel mechanism (12; 17). IL910 may 
also explain why Poly(I:C) fails to increase inflammation in cHx/Su rats, as IL910 reduces 
inflammation and thereby cardiac remodeling or PH (19; 46; 47). In addition, IL910 is also 
produced by circulating endothelial progenitor cells and can stimulate protective natural 
killer cells (48). Two potential drawbacks exist with our hypothesis that IL910 mediates 
protective effects in response to Poly(I:C). First, while Poly(I:C) consistently induced IL910 
in rat lung CD117+ EC and in cHx/Su rat lungs, human lung EC showed a less consistent 
Page 17 of 775
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 
18 
upregulation of IL910, indicating that Poly(I:C)9induced upregulation of IL910 may be 
restricted to subpopulations such as CD117+ EC, or that some of the effects of Poly(I:C) 
have been mediated through nearby inflammatory cells, which we have not studied in 
detail in the current work. Second, elevated systemic levels of IL910 have been reported 
in PAH patients (49). This may represent the results of insufficient IL910 signaling in the 
lung vascular lesions (46; 50). 
 Further potential limitations of our study are: 1. the use of lung tissue 
samples from end9stage PAH patients may underestimate the level of apoptosis in active 
PAH vascular lesions; 2. loss of TLR3 may affect other vascular cells and immune cells. 
In conclusion, we provide evidence for loss of TLR3 in pulmonary artery 
endothelium from patients with advanced PAH. We further show that TLR3 deficiency 
promotes endothelial apoptosis and exaggerates severe PH in mice. Treatment with 
dsRNA reduced severe PH in cHx/Su rats, which could depend on induction of TLR3 via 
IL910 in EC. These surprising findings indicate that careful manipulation of TLR3 
expression and signaling could supplement existing therapeutic approaches for the 
treatment of PAH. 
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Double immunofluorescence shows strong immunostaining of TLR3 in vWF+ endothelium 
in pulmonary artery of control subject (arrows). TLR3 staining is partially lost in 
endothelium of PAH pulmonary arteries with increased smooth muscle layer and intima 
thickening. The arrows indicate endothelium with preserved TLR3 expression, whereas 
asterisks indicate endothelium that is TLR3 deficient. In concentric and plexiform lesions, 
TLR3 staining is largely lost in vWF+ endothelium (asterisks). Scale bars: 50 Wm 
(overview on the left), 25 Wm (higher detail images). The dotted boxes in the overview 
images on the left indicate the area that is shown in more detail on the right. Nuclear 
counterstaining with DAPI.  
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() Lower expression of mRNA in pulmonary artery EC (PAEC) (A, n=4 controls vs. 
n=3 PAH) from human PAH patients as compared to control subjects without pulmonary 
vascular disease. (&) Reduced TLR3 protein expression in PAEC from patients with 
PAH by Western blot (B). β9actin was used to ensure equal loading of lanes. 
Semi9quantitative densitometry of TLR3 vs. β9actin confirms reduced TLR3 protein 
expression in PAEC from PAH patients (C). n=4 different cell lines per group. () 
Reduced mRNA expression of TLR3 in the lung tissue from PAH patients (n=5 controls 
vs. n=6 PAH). (.%) Representative Western blot (E) and semi9quantitative densitometry 
(F) show reduction of TLR3 protein expression in lung tissue protein lysate from cHx/Su 
rats at day 21. β9actin was used as loading control. n=3 per group. (!) Representative 
IHC images for TLR3 show less TLR3+ cells (arrows) in endothelial/intima cells in chronic 
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hypoxia and cHx/Su rats. Counterstaining: Mayer's Hematoxylin. Scale bars: 20 Wm. () 
Quantification of TLR3+ intima cells in pulmonary arteries of cHx and cHx/Su rats. n=3 per 
group. (+) Representative images of vWF and α9SMA IHC show increased pulmonary 
artery muscularization in TLR39/9 mice exposed to the cHx/Su protocol compared to 
TLR3+/+ wildtype (WT) mice. In contrast, no substantial change occurred in TLR39/9 mice 
housed in normoxia. Counterstaining with Hematoxylin. Scale bar: 20 Wm. (:/) TLR39/9 
mice have higher RVSP (J), MWT (K) and fraction of muscularized pulmonary arteries (L) 
than TLR3 WT mice when exposed to the cHx/Su protocol, but not when exposed to 
normoxia. n=6912 (J), 397 (K, L). Bars: mean+SEM, scatter plots indicate mean±SEM. 
*
<0.05, **
<0.01, ***
<0.0001 (A, C, D: t9test; F, H: One9way ANOVA; J9L: Two9way 
ANOVA). 
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6() Representative dot plots show increased fraction of Annexin V+ (AV) 79AAD9 
(apoptotic) cells in PAEC from PAH patients. (&) Quantification of AV+ 79AAD9 PAEC 
according to group (n=6 each group). () Representative dot plots indicate increased 
fraction of AV+ 79AAD9 CD117+ rat lung EC after shRNA9mediated knockdown of TLR3. 
() Quantification of AV+ 79AAD9 CD117+ rat lung EC 72h after adenovirus9mediated 
overexpression of shscrm or shTlr3 (n=3 per group). (.) Gene knockdown was confirmed 
by qRT9PCR of rat gene mRNA expression 72h after the beginning of the 
transfection. (%) Representative Western blot shows reduction of TLR3 expression in 
control PAEC 48h after overexpression of cas9 and TLR3 sgRNA (or scramble sgRNA, 
scrm, as control). β9actin was used as loading control. (!) Semi9quantitative densitometry 
(n=3). () Immunofluorescence staining for TLR3 shows strong TLR3 expression in scrm 
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CRISPR PAEC, but loss of TLR3 expression in most TLR3 CRISPR PAEC after 72h. The 
images on the top show an overview (scale bar 50 Wm) and the images on the bottom 
show cells in more detail, with the scrm cells exhibiting a typical cytoplasmic TLR3 
staining pattern. (+) qRT9PCR shows mRNA expression of (RIG9I) and 		
(MDA95) in TLR3 and scrm CRISPR PAEC. (:) Representative dot plots show increased 
fraction of Annexin V+/79AAD9 PAEC following serum starvation (basal endothelial growth 
medium, EGM) and TLR3 knockdown. (") Quantification of AV+/79AAD9 PAEC. n=9 per 
group. (/) Representative differential interference contrast (DIC) images of gap closure 
assay of PAEC after TLR39targeted or scrm CRISPR. Cells from both groups were 
treated with vehicle or 100 WM Z9Asp9CH29DCB. The images show the damage9free gap 
at 0h and 15h. The borders of the gaps are indicated by yellow dotted lines. Scale bar: 
100 Wm. (*) Quantification of percent wound closure after 15h (n=9 per group). 
Mean+SEM. *
<0.05, **
<0.01, ***
<0.001, ****
<0.0001 (B, D, E, G, I: t9test; K, M: 
29way ANOVA). 
 
%	;6/'


',		
',	
	'+!+*1	+/450		44<=
.6() Representative optical sections of images acquired by confocal microscopy show 
that rhodamine9labeled Poly(I:C) (25 Wg/ml) localized to TLR3, RIG9I and MDA95 in 
shscrm9expressing CD117+ EC with normal TLR3 expression. By contrast, in 
shTlr39expressing cells with reduced TLR3 level, Poly(I:C) mainly interacted with RIG9I 
and MDA95. Arrows: colocalization of Poly(I:C) and respective receptor. Scale bars: 10 
Wm. The lower row shows the areas indicated by dotted boxes in the upper row in more 
detail. Counterstaining with DAPI. (&.) shows changes in the Poly(I:C)9induced mRNA 
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expression of genes regulating inflammation and vasotonus/remodeling between 
shscrm9 and shTlr3 EC: 	(B), (Endothelin91, C), (CXCL10, D) and 	(E). 
(%!) Whereas a low dose of Poly(I:C) (0.1 Wg/ml) fails to induce 	(F) or (G) 
mRNA expression in CD117+ EC, high concentration of Poly(I:C) (50 Wg/ml) strongly 
elevates expression of 	and . (+) Poly(I:C)9induced elevation (25 Wg/ml) of 
expression depends upon IL910, as treatment with a neutralizing anti9IL910 antibody (ab) 
abolishes Poly(I:C)9induced upregulation of (H), but enhances Poly(I:C)9induced 
upregulation (I). (:) Representative Western blots from nuclear lysates show 
increased nuclear accumulation (activation) of NF9κB p65 and AP91 c9Jun in Poly(I:C) (25 
Wg/ml) treated CD117+ EC. Lamin B was used as loading control. (") Inhibition of AP91 
with SR11302 (1 WM) significantly reduces Poly(I:C) (25 Wg/ml)9induced IL910 
upregulation. Inhibitor of NF9κB nuclear translocation JSH923 (25 WM) only resulted in a 
non9significant trend. All bars: mean+SEM, n=3 per group, except n=395 per group for K. 
*
<0.05, **
<0.01, ***
<0.001 (One9way ANOVA). 
 
%	16	))	 7 7',2+3
	
)	

	
0-1;4>6() Diagram of 
treatment protocol. (&) Early high dose (10 mg/kg), but not low dose (1 mg/kg), Poly(I:C) 
treatment reduces RVSP. n=5 (veh) and 3 [Poly(I:C)] () High dose early Poly(I:C) 
treatment did not significantly alter echocardiographic RV cardiac output. n=5 (veh) and 3 
[Poly(I:C)]. () Representative vWF IHC demonstrates occlusion of pulmonary arteries 
(arrows) in vehicle (veh)9 and low Poly(I:C) (1 mg/kg), but not in high Poly(I:C) (10 mg/kg, 
3x/week) treated cHx/Su rats after early treatment (day 1921). (.%) High dose, but not 
low dose, early Poly(I:C) treatment reduced the fraction of completely occluded small 
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pulmonary arteries (external diameter >25 and <50 Wm) (E). In contrast, MWT was not 
reduced by high dose Poly(I:C) treatment, instead low dose Poly(I:C) increased MWT (F). 
n=3 per group. (!:) Preventive high dose Poly(I:C) treatment reduced the number of 
cleaved caspase93+ cells (G9H) and PCNA+ cells (I9J) in pulmonary arteries. Low dose 
Poly(I:C) treatment only had a partial (non9significant) effect on apoptosis and 
proliferation. n=3 for each group. ("/) Representative Western blot (K) shows increased 
IL910 protein expression in the lungs of cHx/Su rats treated with high dose Poly(I:C). 
β9actin was used as loading control. (L) Semi9quantitative densitometry calculated vs. 
β9actin and normalized to vehicle. All bars: mean+SEM, scatter plots: mean±SEM. 
*
<0.05. Scale bars: 100 Wm (D), 20 Wm (G, I) (B, E, F, H, J: One9way ANOVA; L: t9test). 
 
%	>6	
2+3		
)
	

0?	6() Diagram of the treatment protocol. (&) 
Delayed high dose (10 mg/kg) Poly(I:C) treatment reduced RVSP in cHx/Su rats with 
established PH (n=6 each group). () Less occlusion of pulmonary arteries with vWF+ EC 
is found after treatment of cHx/Su rats with Poly(I:C) (3x/week, 10 mg/kg) vs. vehicle 
(veh) after PH was established (day 29942). () Histomorphometry revealed that Poly(I:C) 
treatment reduced the fraction of completely occluded small pulmonary arteries (n=394 
per group). (.) There was no change however in MWT of small pulmonary arteries with 
Poly(I:C) treatment (n=3 per group). (%) Late Poly(I:C) treatment improved RV cardiac 
output as measured by echocardiography [veh n=6, Poly(I:C) n=7]. (!:) Therapeutic 
Poly(I:C) treatment decreased the fraction of cleaved caspase93+ cells (G9H) and PCNA+ 
cells (I9J) in the pulmonary artery wall [n=3 per group, except n=4 for PCNA Poly(I:C)]. 
Bars: mean+SEM, scatter plots: mean±SEM. *
<0.05, **
<0.01, ***
<0.001. Scale bar: 
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100 Wm (C), 20 Wm (G, I) (B, E, F, H, J: t9test; D: One9way ANOVA). 
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
	() Lower 
expression of TLR3 mRNA in pulmonary artery EC (PAEC) (A, n=4 controls vs. n=3 PAH) from human PAH 
patients as compared to control subjects without pulmonary vascular disease. ( ) Reduced TLR3 protein 
expression in PAEC from patients with PAH by Western blot (B). β+actin was used to ensure equal loading of 
lanes. Semi+quantitative densitometry of TLR3 vs. β+actin confirms reduced TLR3 protein expression in PAEC 
from PAH patients (C). n=4 different cell lines per group. (!) Reduced mRNA expression of TLR3 in the lung 
tissue from PAH patients (n=5 controls vs. n=6 PAH). (") Representative Western blot (E) and semi+
quantitative densitometry (F) show reduction of TLR3 protein expression in lung tissue protein lysate from 
cHx/Su rats at day 21. β+actin was used as loading control. n=3 per group. (#) Representative IHC images 
for TLR3 show less TLR3+ cells (arrows) in endothelial/intima cells in chronic hypoxia and cHx/Su rats. 
Counterstaining: Mayer's Hematoxylin. Scale bars: 20 ;m. () Quantification of TLR3+ intima cells in 
pulmonary arteries of cHx and cHx/Su rats. n=3 per group. ($) Representative images of vWF and α+SMA 
IHC show increased pulmonary artery muscularization in TLR3+/+ mice exposed to the cHx/Su protocol 
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compared to TLR3+/+ wildtype (WT) mice. In contrast, no substantial change occurred in TLR3+/+ mice housed 
in normoxia. Counterstaining with Hematoxylin. Scale bar: 20 ;m. (%) TLR3+/+ mice have higher RVSP (J), 
MWT (K) and fraction of muscularized pulmonary arteries (L) than TLR3 WT mice when exposed to the 
cHx/Su protocol, but not when exposed to normoxia. n=6+12 (J), 3+7 (K, L). Bars: mean+SEM, scatter plots 
indicate mean±SEM. *<0.05, **<0.01, ***<0.0001 (A, C, D: t+test; F, H: One+way ANOVA; J+L: Two+
way ANOVA).  
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	 () 
Representative dot plots show increased fraction of Annexin V+ (AV) 7AAD (apoptotic) cells in PAEC from 
PAH patients. () Quantification of AV+ 7AAD PAEC according to group (n=6 each group). () 
Representative dot plots indicate increased fraction of AV+ 7AAD CD117+ rat lung EC after shRNAmediated 
knockdown of TLR3. () Quantification of AV+ 7AAD CD117+ rat lung EC 72h after adenovirusmediated 
overexpression of shscrm or shTlr3 (n=3 per group). (
) Gene knockdown was confirmed by qRTPCR of rat 
 gene mRNA expression 72h after the beginning of the transfection. () Representative Western blot 
shows reduction of TLR3 expression in control PAEC 48h after overexpression of cas9 and TLR3 sgRNA (or 
scramble sgRNA, scrm, as control). βactin was used as loading control. ( ) Semiquantitative densitometry 
(n=3). (!) Immunofluorescence staining for TLR3 shows strong TLR3 expression in scrm CRISPR PAEC, but 
loss of TLR3 expression in most TLR3 CRISPR PAEC after 72h. The images on the top show an overview 
(scale bar 50 <m) and the images on the bottom show cells in more detail, with the scrm cells exhibiting a 
typical cytoplasmic TLR3 staining pattern. (") qRTPCR shows mRNA expression of  (RIGI) and 	
	 
(MDA5) in TLR3 and scrm CRISPR PAEC. (#) Representative dot plots show increased fraction of Annexin 
V+/7AAD PAEC following serum starvation (basal endothelial growth medium, EGM) and TLR3 knockdown. 
($) Quantification of AV+/7AAD PAEC. n=9 per group. () Representative differential interference contrast 
(DIC) images of gap closure assay of PAEC after TLR3targeted or scrm CRISPR. Cells from both groups 
were treated with vehicle or 100 <M ZAspCH2DCB. The images show the damagefree gap at 0h and 15h. 
The borders of the gaps are indicated by yellow dotted lines. Scale bar: 100 <m. (%) Quantification of 
percent wound closure after 15h (n=9 per group). Mean+SEM. *<0.05, **<0.01, ***<0.001, 
****<0.0001 (B, D, E, G, I: ttest; K, M: 2way ANOVA).  
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
 !"#$%& ##'()&	 () Representative optical 
sections of images acquired by confocal microscopy show that rhodaminelabeled Poly(I:C) (25 "g/ml) 
localized to TLR3, RIGI and MDA5 in shscrmexpressing CD117+ EC with normal TLR3 expression. By 
contrast, in shTlr3expressing cells with reduced TLR3 level, Poly(I:C) mainly interacted with RIGI and 
MDA5. Arrows: colocalization of Poly(I:C) and respective receptor. Scale bars: 10 "m. The lower row shows 
the areas indicated by dotted boxes in the upper row in more detail. Counterstaining with DAPI. (*)) shows 
changes in the Poly(I:C)induced mRNA expression of genes regulating inflammation and 
vasotonus/remodeling between shscrm and shTlr3 EC:  (B),  (Endothelin1, C), 	
 (CXCL10, 
D) and  (E). () Whereas a low dose of Poly(I:C) (0.1 "g/ml) fails to induce  (F) or  (G) mRNA 
expression in CD117+ EC, high concentration of Poly(I:C) (50 "g/ml) strongly elevates expression of  
and . (+) Poly(I:C)induced elevation (25 "g/ml) of Tlr3 expression depends upon IL10, as treatment 
with a neutralizing antiIL10 antibody (ab) abolishes Poly(I:C)induced upregulation of Tlr3 (H), but 
Page 38 of 775
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 
enhances Poly(I:C)induced Cxcl10 upregulation (I). (,) Representative Western blots from nuclear lysates 
show increased nuclear accumulation (activation) of NFκB p65 and AP1 cJun in Poly(I:C) (25 "g/ml) 
treated CD117+ EC. Lamin B was used as loading control. (-) Inhibition of AP1 with SR11302 (1 "M) 
significantly reduces Poly(I:C) (25 "g/ml)induced IL10 upregulation. Inhibitor of NFκB nuclear 
translocation JSH23 (25 "M) only resulted in a nonsignificant trend. All bars: mean+SEM, n=3 per group, 
except n=35 per group for K. *<0.05, **<0.01, ***<0.001 (Oneway ANOVA).  
 
212x285mm (300 x 300 DPI)  


Page 39 of 775
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 
)ΛϑΞΥΗ3ΥΗΨΗΘWΛΨΗWΥΗDWΠΗΘWΖΛWΚΚΛϑΚΕΞWΘΡWΟΡΖΓΡςΗΓς51∃3ΡΟ∴,&ΥΗΓΞΦΗςςΗΨΗΥΗ3+ΛΘΓΞΦΗΓΕ∴ΦΚΥΡΘΛΦΚ∴ΣΡ[ΛDDΘΓ
68∃∋ΛDϑΥDΠΡΙWΥΗDWΠΗΘWΣΥΡWΡΦΡΟ%(DΥΟ∴ΚΛϑΚΓΡςΗΠϑΝϑΕΞWΘΡWΟΡΖΓΡςΗΠϑΝϑ3ΡΟ∴,&WΥΗDWΠΗΘWΥΗΓΞΦΗς
5963Θ ΨΗΚDΘΓ>3ΡΟ∴,&≅&+ΛϑΚΓΡςΗΗDΥΟ∴3ΡΟ∴,&WΥΗDWΠΗΘWΓΛΓΘΡWςΛϑΘΛΙΛΦDΘWΟ∴DΟWΗΥΗΦΚΡΦDΥΓΛΡϑΥDΣΚΛΦ59ΦDΥΓΛDΦ
ΡΞWΣΞWΘ ΨΗΚDΘΓ>3ΡΟ∴,&≅∋5ΗΣΥΗςΗΘWDWΛΨΗΨ:),+&ΓΗΠΡΘςWΥDWΗςΡΦΦΟΞςΛΡΘΡΙΣΞΟΠΡΘDΥ∴DΥWΗΥΛΗςDΥΥΡΖςΛΘΨΗΚΛΦΟΗΨΗΚ
DΘΓΟΡΖ3ΡΟ∴,&ΠϑΝϑΕΞWΘΡWΛΘΚΛϑΚ3ΡΟ∴,&ΠϑΝϑ[ΖΗΗΝWΥΗDWΗΓΦ+[6ΞΥDWςDΙWΗΥΗDΥΟ∴WΥΗDWΠΗΘWΓD∴()
+ΛϑΚΓΡςΗΕΞWΘΡWΟΡΖΓΡςΗΗDΥΟ∴3ΡΟ∴,&WΥΗDWΠΗΘWΥΗΓΞΦΗΓWΚΗΙΥDΦWΛΡΘΡΙΦΡΠΣΟΗWΗΟ∴ΡΦΦΟΞΓΗΓςΠDΟΟΣΞΟΠΡΘDΥ∴DΥWΗΥΛΗςΗ[WΗΥΘDΟ
ΓΛDΠΗWΗΥ!DΘΓΠ(,ΘΦΡΘWΥDςW0:7ΖDςΘΡWΥΗΓΞΦΗΓΕ∴ΚΛϑΚΓΡςΗ3ΡΟ∴,&WΥΗDWΠΗΘWΛΘςWΗDΓΟΡΖΓΡςΗ3ΡΟ∴,&
ΛΘΦΥΗDςΗΓ0:7)Θ ΣΗΥϑΥΡΞΣ∗−3ΥΗΨΗΘWΛΨΗΚΛϑΚΓΡςΗ3ΡΟ∴,&WΥΗDWΠΗΘWΥΗΓΞΦΗΓWΚΗΘΞΠΕΗΥΡΙΦΟΗDΨΗΓΦDςΣDςΗΦΗΟΟς∗
+DΘΓ3&1∃ΦΗΟΟς,−ΛΘΣΞΟΠΡΘDΥ∴DΥWΗΥΛΗς/ΡΖΓΡςΗ3ΡΟ∴,&WΥΗDWΠΗΘWΡΘΟ∴ΚDΓDΣDΥWΛDΟΘΡΘςΛϑΘΛΙΛΦDΘWΗΙΙΗΦWΡΘDΣΡΣWΡςΛςDΘΓ
ΣΥΡΟΛΙΗΥDWΛΡΘΘ ΙΡΥΗDΦΚϑΥΡΞΣ./5ΗΣΥΗςΗΘWDWΛΨΗ:ΗςWΗΥΘΕΟΡW.ςΚΡΖςΛΘΦΥΗDςΗΓ,/ΣΥΡWΗΛΘΗ[ΣΥΗςςΛΡΘΛΘWΚΗΟΞΘϑςΡΙΦ+[6Ξ
ΥDWςWΥΗDWΗΓΖΛWΚΚΛϑΚΓΡςΗ3ΡΟ∴,&DΦWΛΘΖDςΞςΗΓDςΟΡDΓΛΘϑΦΡΘWΥΡΟ/6ΗΠΛΤΞDΘWΛWDWΛΨΗΓΗΘςΛWΡΠΗWΥ∴ΦDΟΦΞΟDWΗΓΨςDΦWΛΘDΘΓ
ΘΡΥΠDΟΛ]ΗΓWΡΨΗΚΛΦΟΗ∃ΟΟΕDΥςΠΗDΘ6(0ςΦDWWΗΥΣΟΡWςΠΗDΘ6(036ΦDΟΗΕDΥςΠ∋Π∗,%()+−
2ΘΗΖD∴∃129∃/WWΗςW
Page 40 of 775
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 



	

 !"	 (#) 	
	


$
	

	 !"#$"%&#'(
)



	
%*+,-.
	
#$"%
/$%0
	***#%&12341%#
	

	*

	


	
		
'/34

&5%

%*6+5
		
%
	
'/
)
		
* !
	&


7*'(0
'89'()5
	


*3/-:3#;<-3=	
%7'/
0$
'4
;<
9>	-".60
	?".6@AB0@@A0@@@A
"&C	01C	:0>0.0,0#0=3DE3%<;E!<

Page 41 of 775
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 
1 
ONLINE DATA SUPPLEMENT 
Toll-like receptor 3 is a therapeutic target for Pulmonary Hypertension 
Daniela Farkas *, A. A. Roger Thompson *, Aneel 5Bhagwani, Schuyler Hultman, 
Hyun Ji, Naveen Kotha, Grant Farr, Nadine D. Arnold, Adam Braithwaite, Helen 
Casbolt, Jennifer E. Cole, Ian Sabroe, Claudia Monaco, Carlyne D. Cool, Elena A. 
Goncharova, Allan Lawrie, Laszlo Farkas
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DETAILED METHODS 
Animal models and strains 
For chronic hypoxia (cHx) exposure, male animals were placed in a normobaric 
nitrogen dilution chamber (inspiratory oxygen fraction 10%) and for 21 days. The 
following strains were used: Sprague Dawley rats (Envigo laboratories, Indianapolis, 
IN), C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) and TLR3 knockout mouse 
strain B6;129S1-Tlr3tm1Flv/J (C57BL/6 background) (sources: Prof. Claudia Monaco, 
University of Oxford, UK and Jackson Laboratories). The cHx/Su model was employed 
as published previously (E1; E2): male Sprague Dawley rats received a single 
subcutaneous (s.c.) injection of SU5416 (20 mg/kg, Millipore-Sigma, St. Louis, MO). 
Mice were housed in cHx for 21 days with weekly s.c. injections of SU5416 (20 mg/kg) 
as published by Ciuclan et al. (E3). Rats were exposed to cHx for 1, 6 (early study part) 
and 21 days (preventive treatment strategy) and 28 days (therapeutic treatment 
strategy). In the therapeutic treatment strategy, exposure to cHx for 28 days was 
followed by 14 days of housing in normoxia (room air).  
Note on TLR3 WT mice used in this study 
TLR3-/- mice are available commercially as homozygous knockout animals on a 
C57BL/6 background and the controls recommended by the supplier (Jackson Labs) 
are wildtype C57BL/6 mice, which we used in our study. Generating TLR3+/+ littermates 
would have required several generations of backcrosses between TLR3-/- and C57BL/6 
mice. 
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Isolation of rat CD117+ endothelial cells 
Because of our previous publication that suggests an important contribution of 
CD117+ EC to the occlusive pulmonary arteriopathy that is characteristic of cHx/Su rats 
(E2), we isolated CD117+ EC from the lung periphery of naive adult Sprague Dawley rats 
(8-10 weeks, Envigo laboratories). After resection, a lung single cell suspension was 
prepared using a modified protocol according to van Beijnum et al. (E4). In short, lung 
tissue was dissected into <1mm3 pieces followed by enzymatic digestion with digested in 
0.1% collagenase II/ 2.5 U/ml dispase solution (both from Thermo Fisher Scientific, 
:DOWKDP0$ IRUPLQDWÛ&7KLVZDV IROORZHGE\DQRWKHU LQFXEDWLRQZLWK
DNase (Sigma-$OGULFK 6W /RXLV 02 IRU  PLQXWHV DW Û& &'+ cells were 
obtained by immunomagnetic sorting using magnets and the “FITC Any Species positive 
selection” kit from Stem Cell Technologies (Vancouver, BC). Then, hematopoieitic cells 
were depleted from the cell pool by negative sorting with bead-conjugated antibodies 
directed against CD5, CD11b/c and CD45 (pan-CD45) using Pluribeads (Pluribeads, 
Leipzig, Germany) according to the manufacturer’s recommendation. To enrich the 
endothelial fraction, CD31+ cells were selected from these CD117+ and hematopoietic 
lineage negative (lin-) cells using pluribeads. The hereby obtained CD117+ lin– CD31+ 
cells (CD117+ EC) were cultured on type I collagen coated dishes with EGM-2MV medium 
/RQ]D:DONHUVYLOOH0'LQDKXPLGLILHGFHOOLQFXEDWRUDWÛ&DQG&2 
Characterization of CD117+ endothelial cells 
CD117+ EC were characterized by flow cytometry according to standard protocols 
for expression of EC marker von Willebrand Factor (vWF) and lack of hematopoietic 
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markers CD45 and CD11b/c using a FACS Canto (BD Biosciences), in the Flow 
cytometry Core facility at VCU (see section on flow cytometry for further details). For 
functional characterization, angiogenic tube formation assay was performed by seeding 
2×104 CD117+ EC per well in EGM-2MV on matrigel (BD Biosciences) on a 96 well plate. 
In addition, the clonal expansion potential was determined by a clonal expansion assay: 
CD117+ EC were seeded at a limiting dilution of 1 cell per well in 96 well plates. Then, the 
growth of clonal colonies was identified by differential interference contrast (DIC) 
microscopy after 7 days using an Olympus IX70 inverted microscope with CellSens 
software (both Olympus, Waltham, MD). 
Human lung microvascular EC (HLMVEC) 
HLMVEC were isolated from explanted lung tissue by CD31 magnetic bead 
selection (Dynabeads, Thermo Fisher Scientific). 
Human umbilical vein EC (HUVEC) 
HUVEC pooled from several donors were obtained from a commercial vendor 
(Lonza Clonetics, Walkersville, MD). 
Cell culture experiments 
Human pulmonary artery EC (PAEC), HLMVEC and HUVEC 
PAEC and HUVEC were cultured with complete EGM-2 medium (Lonza, 
Walkersville, MD and Promocell, Heidelberg, Germany), and HLMVEC were grown in 
basal media supplemented with endothelial cell growth supplement (ScienCell 
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Research Laboratories Inc, Carlsbad, CA), 5% foetal bovine serum and 
penicillin/streptomycin. For apoptosis assay and baseline TLR3 expression, cells were 
removed after 24h for flow cytometry for Annexin V binding or for quantitative real-time 
PCR (qRT-PCR). For Western blot, cells were grown on 10 cm dishes until 
subconfluency and protein isolation and Western blots were prepared as indicated 
under Western blotting.  
CRISPR gene editing 
For Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 
interference, PAEC were transfected with 100 multiplicity of infection (MOI) of 
adenovirus encoding Cas9 nuclease (Ad-CMV-Cas9, Vector Biolabs, Malvern, PA) and 
multiplicity of infection (MOI) 100 of adenovirus encoding a single guidance RNA 
(sgRNA) targeting a 20 base sequence in exon 2 of human TLR3 (Ad-TLR3-sgRNA-
CRISPRi) or scrambled control sgRNA (Ad-scrm-sgRNA-CRISPRi) (both Applied 
Biological Materials, Richmond, BC, Canada). Similar co-transfection approaches using 
two viral vectors expressing Cas9 and sgRNA have been used successfully in other cell 
lines (E5; E6). The virus was removed after 16 hours. Knockout efficiency was 
confirmed using Western blot and immunocytochemistry. We did not select for knockout 
clones, because the PAEC cultures were in average in passage 5 or 6 at transfection 
and we have observed in previous experiments that during selection and expansion, EC 
will likely reach a critical number of population doublings and become growth-arrested. 
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Immunocytochemistry 
For immunocytochemistry to detect TLR3, a protocol similar to a previously 
published protocol was used (E7). In brief, PAEC were passaged after CRISPR and 
grown on LabTek chamber slides (Nalgene NUNC, ThermoFisher Scientific, Rochester, 
NY). For staining, cells were fixed with 10% formalin for 10 min. Then cells were 
permeabilized with 0.5 Triton-X for 10 min and blocked with 1% BSA for 30 min. The 
cells were incubated with the primary antibody (anti-TLR3, LS Bioscience) in 1% BSA 
overnight at 4°C. Then, cells were incubated with AF488 -labeled secondary antibody 
(ThermoFisher Scientific) for 1h and counterstained with DAPI. The stained slides were 
mounted with slowfade and imaged with Olympus IX70 inverted microscope and 
CellSens software. Images were assembled with Fiji software (E8).  
Serum starvation 
For serum starvation, cells were cultured in basal growth media (no FBS, no 
growth factors) for 24h. Annexin V staining and analysis were performed as described 
under flow cytometry. 
Migration/gap closure assay 
For migration/gap closure assay, Ibidi chambers with defined cell-free gaps were 
used (Ibidi, Madison, WI). In brief, scrm and TLR3 CRISPRi cells were seeded in 6 well 
plates at 5000 cells/cm2 and grown until confluent. The divider was removed, leaving a 
defined cell-free gap. Cells were cultured with complete EGM2 or, for serum starvation 
experiments, with basal EGM (no FBS, no growth factors). Images were obtained at 0h 
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and 15h after initiating the gap closure with an Olympus IX70 inverted microscope and 
CellSens software. During the gap closuUHSHULRG WKHFHOOVZHUH WUHDWHGZLWKȝ0
(3S)-5-(2,6-dichlorobenzoyl)oxy-4-oxo-3-(phenylmethoxycarbonylamino) pentanoic acid 
(Z-Asp-CH2-DCB) (Bachem, Torrance, CA) or vehicle. Measurements were performed 
using Fiji software (E8). Analysis was done according to a modified protocol similar to 
Yue et al. (E9). 
Caspase 3/7 activity and reactive oxygen species activity. 
Caspase activity was determined using Capase-Glo 3/7 (Promega, Madison, WI) 
and normalized for cell number using CellTiter-Glo (Promega). Reactive oxygen species 
(ROS) were measured using ROS-Glo (Promega) and normalized for cell number using 
CellTiter-Glo. Values are given as n-fold vs. control samples. Luminescence was 
measured using a Synergy H1 plate reader (BioTek, Winooski, VT) or a GloMax Explorer 
luminiscence plater reader (Promega). 
Rat CD117+ endothelial cell experiments 
Rat CD117+ EC were cultured with EGM-2MV medium and seeded at 3000 
cells/cm2 in 6 well plates for experiments. Cells were stimulated with the following 
conditions: extracellular addition of Poly(I:C) (Tocris, Minneapolis, MN) at 0.1, 25 or 50 
ȝJPOIRUKWUDQVIHFWLRQRI3RO\,&DWȝJPOQHXWUDOL]LQJSRO\FORQDOJRDWDQWL-rat-IL-
DQWLERG\DWȝJPO5	'6\VWHPV0LQQHDSROLV0165DWȝ07RFULV-6+-
DWȝ06DQWD&UX]%LRWHFKQRORJ\6DQWD&UX]&$)RUWUDQVIHFWLRQRI3RO\,&
Effectene transfection reagent (Qiagen, Germantown, MD) was used, combining ȝJ
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3RO\,&  ȝO HQKDQFHU DQG  ȝO (IIHFWHQH UHDJHQW SHU  PO RI FXOWXUH PHGLD 7R
overexpress single hairpin (sh) RNA directed against rat TLR3 or scrambled (control) 
shRNA in CD117+ EC, Ad-r-shTLR3 and Ad-shscrm adenoviruses were obtained from 
Vector Biolabs (Malvern, PA). CD117+ (&ZHUHLQFXEDWHGZLWKDGHQRYLUXVHVDWȂȅǿRI
50 for 16h, then adenovirus was removed and fresh media added. After 72h, gene 
knockdown was verified and cells were stimulated with Poly(I:C) or vehicle. 
For immunocytochemistry/stimulation with rhodamine-labelled Poly(I:C), cells 
were seeded at 5000/cm2 LQȝ-Slide VI 0.4 chambers (Ibidi, Madison, WI) according to 
the manufacturer’s recommendation. TLR3 knockdown was established by transfection 
with Ad-r-shTLR3 (control: Ad-shscrm) as described above. 72h after initial adenovirus 
inoculation, 25 ng/ml rhodamine-labeled Poly(I:C) (Invivogen, San Diego, CA) was added 
to all wells for 24h. Then, media was removed and cells were fixed with 10% 
formalin/phosphate-buffered saline (PBS) for 10 min at room temperature. Then, the cells 
were permeabilized with 0.5% Triton-X/PBS for 10 min at room temperature, followed by 
blocking with 1% bovine serum albumin (BSA)/PBS for 30 min. The cells were incubated 
with the primary antibodies anti-TLR3 (LifeSpan Biosciences, Seattle, WA), anti-RIG-I 
(Abcam, Cambridge, MA) and anti-MDA-5 (LifeSpan Biosciences) dissolved in 1% 
%6$3%6RYHUQLJKWDWÛ&7KHQWKHFHOOVZHUHLQFXEDWHGZLWK$)-labeled secondary 
antibodies (Invitrogen, Carlsbad, CA) in 1%BSA/PBS for 1 h at room temperature, 
followed by counterstaining with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen). 
Images were acquired with a Zeiss LSM710 confocal microscope and Zen software 
(Zeiss, Peabody, MA), located in the Microscopy Core Facility at Virginia Commonwealth 
University. Images were assembled in Fiji. 
Page 50 of 77Page 49 of 75
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 
9 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
RNA isolation was carried out using the RNeasy isolation kit (Qiagen, 
Germantown, MD) or the Quick RNA mini-prep (Zymo Research, Irvine, CA) according to 
the manufacturer’s recommendation. For transcription of RNA to cDNA, RNA first 
underwent treatment with DNase I (Invitrogen, Thermo Fisher Scientific, Waltham, MD) 
for 15 min at room temperature, followed by inactivation of DNase with 
(WK\OHQHGLDPLQHWHWUDDFHWLF DFLG DQG LQFXEDWLRQ DW Û& IRU  PLQ 7KH UHYHUVH
transcriptase (RT) reaction was done with the High capacity RT reaction kit (Applied 
Biosystems, Thermo Fisher Scientific) according to the manufacturer’s recommendation. 
For qRT-PCR, obtained cDNA was diluted 1:10 in nuclease-free water and master mixes 
were prepared with primer and iTaq SYBR green master mix (Biorad, Hercules, CA) or 
PowerUp SYBR green master mix (Thermo Fisher Scientific). Primers were obtained from 
a commercial source (Quantitect, Qiagen or Kicqstart, Sigma-Aldrich, St. Louis, MO) or 
designed and manufactured (Stanford University, see Table E1). QRT-PCR was run in 
96 or 384 well plates in a CFX96 or CFX384 touch qRT-PCR system (Biorad) with the 
followiQJ SURJUDP LQLWLDO VWHS DW Û& IRU  V 7KHQ  F\FOHV ZLWK WKHQ IROORZLQJ
FRQGLWLRQVÛ&IRUVIROORZHGE\Û&IRUV$IWHUDILQDOVWHSRIÛ&IRUV
DPHOWLQJFXUYHZDVJHQHUDWHGE\LQFUHDVLQJWKHWHPSHUDWXUHIURPWRÛ&LQÛ&
increments/5 s. The following primers were used for amplification: Quantitect (Qiagen): 
human B2M (Hs_B2M_1_SG), human RRN18S (18SRNA, Hs_RRN18S_1_SG), human 
TLR3 (Hs_TLR3_1_SG), rat Tlr3 (Rn_Tlr3_2_SG), human CXCL10 
(Hs_CXCL10_1_SG), rat Cxcl10 (Rn_Cxcl10_1_SG). Kicqstart (Sigma-Aldrich): human 
TBP (forward: FH1_TBP and reverse: RH1_TBP), human DDX58 (forward: FH1_DDX58 
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and reverse: RH1_DDX58), human IFIH1 (forward: FH1_IFIH1 and reverse: RH1_IFIH1), 
human IL6 (forward: FH_IL6 and reverse: RH_IL6), human IL10 (forward: FH2_IL10 and 
reverse: RH2_IL10), human RPS20 (forward: FH1_RPS20 and reverse: RH1_RPS20), 
rat Il10 (forward: FR1_Il10 and reverse: RR1_Il10), rat Edn1 (forward: FR1_Edn1 and 
reverse: RR1_Edn1), rat Gusb (forward: FR1_Gusb and reverse: RR1_Gusb), rat Tbp 
(forward: FR1_Tbp and reverse: RR1_Tbp). For calculation of the results, the most stable 
housekeeping or the two most stable housekeeping genes were identified using the 
relative expression software tool (REST) from Pfaffl et al. (E10) from a set of genes that 
included RRN18S, B2M, GUSB, TBP and RPS20. If two housekeeping genes were used, 
the geometric mean of two housekeeping genes was used as reference. Analysis was 
performed according to the principles set forth by Pfaffl, M. (E11).  
Flow cytometry 
For surface marker expression of CD117+ EC, cells were removed from culture 
vessel and suspended at a concentration of 106 FHOOVȝOIORZUHDFWLRQEXIIHU>IHWDO
bovine serum (FBS)/PBS]. Then, primary labeled antibodies for CD45 and CD11b/c (both 
BD Biosciences) were added for 30 min at room temperature in the dark to detect 
CD11b/c and CD45. For vWF (Abcam), permeabilization using Cytofix/Cytoperm buffer 
and Permwash wash buffer (both BD Bioscience, San Jose, CA) was performed for 20 
min. prior to antibody incubation according to the manufacturer’s recommendations. The 
staining was analyzed on a BD FACS Canto machine and analysis was performed using 
FlowJo software (FlowJo, LLC, Ashland, OR). 
For Annexin V binding assay, allophycocyanin (APC) Annexin V (BD Biosciences) 
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was used according to the manufacturer’s recommendations. 105 cells dissolved in 100 
ȝOELQGLQJEXIIHUZHUHLQFXEDWHGIRUPLQDWURRPWHPSHUDWXUHLQWKHGDUNZLWK-ȝO
RI$3&$QQH[LQ9DQGȝORI-Amino-Actinomycin (7-$$'WKHQGLOXWHGZLWKȝORI
binding buffer. The staining was analyzed on a BD FACS Canto machine within 1 hr and 
analysis was performed using FlowJo 10 software (FlowJo, LLC, Ashland, OR).  
Lung cell single suspension and flow cytometry staining for inflammatory cells was 
performed as published previously (E1). 
Protein isolation and Western blot 
Whole cell protein lysate was prepared as published previously (E1; E7). For cell 
culture experiments, 10-ȝJ SURWHLQ DQG IRU ZKROH OXQJ WLVVXH SURWHLQ O\VDWH ȝJ
protein was loaded onto Nu-PAGE 4-12% Bis-Tris protein gels and resolved by SDS-
PAGE. Then, protein was blotted onto a nitrocellulose membrane for antibody staining 
and chemiluminiscence detection (Amersham ECL reagent, GE Healthcare Life 
Sciences, Marlborough, MA). The following antibodies were used for detection: TLR3 
(LifeSpan Biosciences), TLR3 (abcam), p65 (Cell Signaling), c-Jun (Cell Signaling), 
Lamin B (Santa Cruz Biotechnology), IL-10 (5	'6\VWHPVDQGDVORDGLQJFRQWUROȕ-
actin (Sigma). Images were obtained with a Chemidoc XRS+ gel imager with ImageLab 
software (Biorad, Hercules, CA), or developed with Blue Autoradiography films 
(GeneMate, VWR, Radnor, PA) and scanned with an Perfection V700 scanner (Epson, 
Long Beach, CA).  
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Immunohistochemistry/immunofluorescence staining and morphometry 
Immunohistochemistry (IHC) and double/triple Immunofluorescence (IF) stainings 
were performed according to established protocols as previously published (E1; E2; E7). 
The following primary antibodies were used: caveolin-1 (Cell Signaling Technologies, 
Danvers, MA), cleaved caspase-3 (Cell Signaling Technologies), proliferating cell nuclear 
antigen (PCNA, Cell Signaling Technologies), TLR3 (LifeSpan Bioscences), TLR3 
DEFDP Į-SMA (Sigma-Aldrich), vWF (DAKO cytomation). For Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and TLR3 double IF, lung 
tissue sections were stained using the ApopTag Fluorescein In Situ Apoptosis Detection 
Kit (Millipore Sigma, Burlington, MA) and TLR3 antibody (abcam) according to the 
manufacturer's recommendation similar to previously published protocols (E7; E12). To 
quantify IHC staining for cleaved caspase-3, PCNA and TLR3, the number of positive 
cells and total cells were enumerated in 10 randomly acquired pulmonary arteries per 
animal by a blinded investigator as previously described using the cell counter plugin for 
Fiji (E1; E2; E7). For analysis of cleaved caspase-3 in human lung tissue sections and 
TLR3 in rat lungs, cleaved caspase-3+ or TLR3+ endothelial/intima cells were counted 
and presented as fraction of total endothelial/intima cells. For analysis of cleaved 
caspase-3+ IHC in the left ventricle (apoptotic index), 5 images of left ventricular tissue 
were randomly acquired at a magnification of 400x. Cleaved caspase-3+ cells were 
counted and presented as fraction of total cells per field of view. 
For analysis of left ventricular capillary density, 5 images of left ventricular tissue 
stained for caveolin-1 (IHC) were randomly acquired at a magnification of 400x. Caveolin-
1+ tissue area (=capillary area) was measured for each image using “color deconvolution” 
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plugin using thresholding and area measurement in Fiji (E8), similar to previous published 
work (E7). To obtain capillary density, caveolin-1+ area was divided by the total tissue 
area. Objectivity in all analyses was further ensured by providing each animal with a 
numerical code to mask treatment groups.  
For measurement RIPXVFXODUL]DWLRQLQSXOPRQDU\DUWHULHVLPDJHVRIĮ-SMA IHC 
stained sections were randomly taken with an AXIO imager.A1 microscope, Axiocam HRc 
camera and Axiovision software (all Zeiss, Jena, Germany) at 100× magnification. 
Objectivity was ensured by providing each animal with a numerical code to mask 
treatment groups. Media thickness (MT) and external diameter (ED) were measured as 
published before and media wall thickness (MWT) was calculated according to the 
formula: MWT=[(2×MT)/ED]×100% (E7). For MWT in mice, MT was obtain in slides with 
,+& VWDLQLQJ IRU Į-SMA and was divided by the vessel area and provided as percent 
MWT. Pulmonary arteries were categorized as follows: small-VL]HGȝP('P
medium-VL]HGȝP('ȝP)RUHDFKDQLPDO30-40 pulmonary arteries were 
measured in two orthogonal directions using Fiji image analysis software (E8). For 
analysis of chronic hypoxic PH in rats and chronic hypoxia/SU5416 in mice, the 
pulmonary arteries were further classified as ‘muscularized’, ‘partially muscularized’ and 
‘non-muscularized’. 
Vascular occlusion was quantified in sections stained for vWF IHC as published 
previously to obtain the fraction of small-sized pulmonary arteries that were classified as 
‘patent’, ‘partially occluded’ and ‘completely obstructed’ (E1). Objectivity was here also 
ensured by providing each animal with a numerical code to mask treatment groups, 
random acquisition of images and blinded investigator. 
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Supplemental Table 
Gene name direction sequence 
DDX58 forward TACGCCTTCAGACATGGGAC 
reverse TGGCTTGGGATGTGGTCTAC 
IFIH1 forward GGAGTCAAAGCCCACCATCT 
reverse GTGAGCAACCAGGACGTAGG 
IL10 forward GACTTTAAGGGTTACCTGGGTTG 
reverse TCACATGCGCCTTGATGTCTG 
CXCL10 forward GTGGCATTCAAGGAGTACCTC 
reverse TGATGGCCTTCGATTCTGGATT 
IL6 forward TCCACAAGCGCCTTCGGTCC 
reverse TGTCTGTGTGGGGCGGCTACA 
RRN18S forward CGGCTACCACATCCAAGGAA 
reverse GCTGGAATTACCGCCGCT 
Supplemental Table E1. Designed primer sequences for human genes. 
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SUPPLEMENTAL FIGURE LEGENDS 
Figure E1. TLR3 deficiency is associated with endothelial apoptosis in situ. (A) 
Representative images (confocal microscopy) show strong endothelial TLR3 staining 
and no TUNEL+ (apoptotic) cells in the intima of pulmonary arteries from control patient. 
Some TUNEL+ cells are found in a perivascular infiltrate (asterisk). In contrast, PAH 
patients had reduced intimal TLR3 staining in remodeled pulmonary arteries and 
TUNEL+ intima cells were found in areas with low cellular TLR3 expression (arrow). In 
the bottom row, small TUNEL+ apoptotic bodies are found in the intima in a TLR3 
deficient intima lesion area (arrows). The inserts show the indicated areas in more 
GHWDLO6FDOHEDUVȝPRYHUYLHZRQWKHOHIWȝPKLJKHUGHWDLOLPDJHVRQWKH
right). (B) Cleaved caspase-3+ ECs were only very rarely detected in pulmonary arteries 
from control subjects, but pulmonary arteries from PAH patients contained cleaved 
caspase-3+ intima cells (arrow: representative cleaved caspase-3+ EC). The insert 
VKRZVWKHDUHDLQGLFDWHGE\DGRWWHGER[LQPRUHGHWDLO6FDOHEDUVȝPFRQWURO
ȝP3$+C) Fraction of cleaved caspase-3+ EC/intima cells in pulmonary arteries 
from control subjects and PAH patients. n=3 controls and 5 PAH patients (n=7-10 
vessels for each patient). (D) Representative images for cleaved caspase-3 IHC shows 
more cleaved caspase-3+ cells (mainly EC) in remodeled pulmonary arteries of TLR3-/- 
mice exposed to cHx/Su as compared with cHx/Su WT mice. (E) Quantification of % 
cleaved caspase-3+ cells in WT and TLR3-/- mice exposed to cHx/Su (n=5 per group). 
Mean+SEM. *P<0.05, **P<0.01 (C, E: t-test) 
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Figure E2. Cleaved caspase+ cells in pulmonary arteries of early cHx/Su rats and 
normoxic and chronic hypoxic TLR3 KO mice. (A) Representative images show 
presence of cleaved caspase-3+ cells in the pulmonary artery wall of cHx/Su day 1 and 6 
UDWV6FDOHEDUȝPB) Quantification of the fraction of cleaved caspase-3+ cells in 
the pulmonary arteries of naive, cHx/Su day 1 and cHx/Su day 6 rats. mean+SEM, n=3 
per group. (One-way ANOVA) 
Figure E3. Characterization of rat lung CD117+ lin- CD31+ EC (CD117+ EC). CD117+ 
EC form angiogenic tubes in matrigel (A) and are clonally expandable (B), suggesting a 
SURJHQLWRUFHOOSKHQRW\SHRIWKHVHFHOOV6FDOHEDUVȝPPDWULJHOȝPFORQDO
assay). (C) The histograms show representative flow cytometry results indicating that 
CD117+ EC express EC marker vWF, but lack expression of hematopoietic markers 
CD11b/c and CD45. 
Figure E4. Loss of TLR3 expression is maintained in TLR3 CRISPR PAEC over 
passage. Representative images of immunocytochemistry demonstrate that most of the 
TLR3 CRISPR PAEC remain TLR3- DIWHUSDVVDJH6FDOHEDUȝP1XFOHDUVWDLQLQJ
with DAPI. 
Figure E5. Transfection vs. extracellular addition of Poly(I:C) in CD117+ rat lung EC. 
3RO\,&WUDQVIHFWLRQDWDORZHUGRVHȝJPOZKLFKE\SDVVHVHQGRVRPDOSURFHVVLQJ
of dsRNA, increases mRNA expression of Il10 (A), Tlr3 (B) and Cxcl10 (C) stronger than 
H[WUDFHOOXODU DGGLWLRQ  ȝJPO PHDQ6(0 Q  H[SHULPHQWVJURXS  P<0.01, *** 
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P<0.001 (One-way ANOVA). 
Figure E6. Comparative gene expression following Poly(I:C) human lung 
microvascular EC (HLMVEC) and human umbilical vein EC (HUVEC). (A-B) Gene 
expression of TLR3, DDX58 (RIG-I), IFIH1 (MDA-5), IL-6, CXCL10 and IL10 in 
+/09(&$DQG+89(&%WUHDWHGZLWKȝJPO3RO\,&DQGȝJPO3RO\,&IRU
24h. There are substantial differences between the two types of EC: HUVEC have 
higher induction of DDX58 and IFIH1, but fail to induce CXCL10 and IL10 compared to 
HLMVEC. mean+SEM. n=4-6 per group. *P<0.05, **P<0.01, ***P<0.001 (One-way 
ANOVA). 
Figure E7. Comparison of Poly(I:C) effects on caspase 3/7 activity and reactive 
oxygen species (ROS) production. (A) Caspase 3/7 activity shows concentration-
dependent increase in Poly(I:C)-treated HLMVEC under serum starvation (basal EGM). 
No increase in caspase 3/7 activity was found with Poly(I:C) stimulation in PAEC. n=4 
(HLMVEC) and 6 (PAEC). (B) High dose of Poly(I:C) induced ROS production in HUVEC 
and PAEC. All bars mean+SEM. n=3 (HUVEC) and 6 (PAEC). **P<0.01, ***P<0.001 
(Two-way ANOVA). 
Figure E8. Treatment of naive rats with high dose Poly(I:C) (10 mg/kg) or vehicle 
for 2 weeks with 3 doses/week. (A) Representative immunohistochemistry for vWF and 
Į-SMA of naive rats treaWHGZLWKYHKLFOHYHKRU3RO\,&6FDOHEDUVȝPB) No 
change in RVSP in Poly(I:C) vs. vehicle. (C) Vehicle and Poly(I:C) treated rats exhibited 
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no relevant degree of occlusion. Rarely, pulmonary arteries had vWF+ cells in the lumen, 
causing classification as "partial" occlusion when the vWF+ area exceeded 25% of the 
luminal area (see arrows in A). (D) Increased MWT in Poly(I:C)-treated naive rats. (E) 
More cleaved caspase-3+ cells were found in the pulmonary artery wall of Poly(I:C) vs. 
vehicle-treated rats, whereas the fraction of PCNA+ cells (F) only showed a trend towards 
higher proliferation rate. mean±SEM (scatter plot) and mean+SEM (bar graphs). n=3 per 
group. *P<0.05 (t-test). 
 
Figure E9. Treatment with TLR3 agonist Poly(I:C) prevents chronic hypoxic PH. 
(A) Diagram of treatment protocol. (B) Poly(I:C) treatment prevented increase in RVSP 
[n=6 veh, n=4 Poly(I:C)]. (C5HSUHVHQWDWLYHLPDJHVIRUĮ-SMA IHC show reduced 
thickness of the pulmonary artery smooth muscle layer in SD rats exposed to cHx after 
treatment with Poly(I:C) (10mg/kg, 3x/week). (D) Echocardiographically measured RV 
cardiac output. [n=6 veh, n=5 Poly(I:C)] (E-F) MWT (E) and fraction of small 
muscularized pulmonary DUWHULHVȝP('ȝP)ZHUHUHGXFHGDIWHU3RO\,&
treatment in cHx rats (n=3 each). (G-J) Representative images (G, I) and quantification 
of fraction of cleaved caspase-3+ (H) and PCNA+ (J) cells (n=3 each) show reduced 
apoptosis and proliferation in the pulmonary arteries after Poly(I:C) treatment. All bars: 
mean+SEM, scatter plots: mean±SEM. *P<0.05 and ***P<0.0001, n.s.=not significant (t-
WHVW6FDOHEDUVȝP&ȝP*, 
 
Figure E10. Preventive Poly(I:C) treatment does not change the fraction of 
inflammatory cells in the lungs of cHx/Su rats. In lung single cell suspensions, the 
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fraction of CD3+ (A), CD4+ (B), CD8+ (C), CD45RA+ (D), CD11b/c+ (E) and granulocyte+ 
(F) cells was measured. Each bar: mean+SEM of n=3. (t-test) 
Figure E11. Capillary density and apoptotic index in the left ventricles of chronic 
hypoxic rats after preventive treatment with vehicle or high-dose Poly(I:C) (day 21). 
The images show representative IHC for caveolin-1 (capillaries) and cleaved caspase-3 
(apoptosis) of the left ventricle from cHx rats treated with vehicle (veh) or 10 mg/kg 
Poly(I:C) from day 1-21 (3x/week). The arrows indicate representative cleaved caspase-
3+ cells. Scale bars: 50 ȝm (caveolin-1), 25 ȝm (cleaved caspase-3). Each bar: 
mean+SEM of n=3. (t-test) 
Figure E12. Capillary density and apoptotic index in the left ventricles of chronic 
hypoxia+SU5416 rats after therapeutic treatment with vehicle or high-dose 
Poly(I:C) (day 42). The images demonstrate representative IHC for caveolin-1 and 
cleaved caspase-3 of the left ventricle from cHx/Su rats treated with vehicle (veh) or 10 
mg/kg Poly(I:C) from day 29-42 (3x/week). The arrows point to representative cleaved 
caspase-3+ cells. Scale bars: 50 ȝm (caveolin-1), 25 ȝm (cleaved caspase-3). Each bar: 
mean+SEM of n=3. *P<0.05, **P<0.01 (t-test). 
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(&) Representative iunohistochemistry for vWF and αSMA of naive rats treated 
with vehicle (veh) or Poly(I:C). Scale bars: 100 'm. (') No change in RVSP in Poly(I:C) vs. vehicle. () 
Vehicle and Poly(I:C) treated rats exhibited no relevant degree of occlusion. Rarely, pulmonary arteries had 
vWF+ cells in the lumen, causing classification as "partial" occlusion when the vWF+ area exceeded 25% of 
the luminal area (see arrows in A). (() Increased MWT in Poly(I:C)treated naive rats. () More cleaved 
caspase3+ cells were found in the pulmonary artery wall of Poly(I:C) vs. vehicletreated rats, whereas the 
fraction of PCNA+ cells () only showed a trend towards higher proliferation rate. mean±SEM (scatter plot) 
and mean+SEM (bar graphs). n=3 per group. *<0.05 (ttest).  
 
53x61mm (300 x 300 DPI)  


Page 72 of 77Page 71 of 75
 AJRCCM Articles in Press. Published on 13-September-2018 as 10.1164/rccm.201707-1370OC 
 Copyright © 2018 by the American Thoracic Society 



	
 !!"!#
($) 	

eatment protocol. (%) Poly(I:C) treatment prevented increase in RVSP [n=6 veh, n=4 Poly(I:C)]. () 
Representative images for α&SMA IHC show reduced thickness of the pulmonary artery smooth muscle layer 
in SD rats exposed to cHx after treatment with Poly(I:C) (10mg/kg, 3x/week). (&) Echocardiographically 
measured RV cardiac output. [n=6 veh, n=5 Poly(I:C)] (') MWT (E) and fraction of small muscularized 
pulmonary arteries (25 8m<ED<50 8m) (F) were reduced after Poly(I:C) treatment in cHx rats (n=3 each). 
((')) Representative images (G, I) and quantification of fraction of cleaved caspase&3+ (H) and PCNA+ (J) 
cells (n=3 each) show reduced apoptosis and proliferation in the pulmonary arteries after Poly(I:C) 
treatment. All bars: mean+SEM, scatter plots: mean±SEM. *<0.05 and ***<0.0001, n.s.=not significant 
(t&test). Scale bars: 100 8m (C), 20 8m (G, I).  
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